文献速递自身免疫性与大疱性皮肤病药疹与重症皮肤不良反应

静脉注射免疫球蛋白对皮肤病患者血液学参数的影响

Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-11-28

该研究基于一例IVIG相关溶血性贫血病例,回顾性分析了16例接受IVIG(1–3 g/kg体重,共35个周期)的皮肤病患者的红细胞和白细胞参数,并在体外检测IVIG对白细胞存活的影响。结果显示高剂量IVIG与红细胞数、血红蛋白和血细胞比容下降及一例溶血性贫血相关,而白细胞减少在大多数受者中出现且与剂量无关;体外实验表明IVIG对中性粒细胞和单核细胞存活呈剂量依赖性损害,淋巴细胞亚群不受影响。部分IVIG制品含血型抗A/抗B抗体,可能解释血液学参数变化。

要点

  • 高剂量IVIG可致红细胞参数下降及溶血性贫血,低剂量未见此关联。
  • IVIG后白细胞减少在大多数受者中出现,与给药剂量无关。
  • 部分IVIG制品含血型抗A/抗B抗体,可能诱导溶血。

核心结论

  • IVIG制品可能含血型特异性抗体,在部分受者中诱导溶血。
  • IVIG应严格按适应症使用,尤其高剂量时建议监测血常规。

研究设计与样本

  • 回顾性分析16例接受IVIG(1–3 g/kg体重,共35个周期)的皮肤病患者的红细胞和白细胞参数。
  • 体外检测IVIG对白细胞存活的影响。

主要发现

  • 高剂量IVIG与红细胞绝对数、血红蛋白和血细胞比容下降及一例溶血性贫血相关,低剂量无此关联。
  • IVIG后白细胞减少发生于绝大多数受者,与给药剂量无关。
  • 体外实验中IVIG对中性粒细胞和单核细胞存活呈剂量依赖性损害,对淋巴细胞亚群无影响。
  • 在多个IVIG制品中检测到大量血型抗A/抗B抗体。

临床怎么用

  • IVIG应严格按适应症使用。
  • IVIG治疗期间监测血常规,尤其在高剂量给药时。

局限性

  • 回顾性分析,样本量小(16例患者,35个周期)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous immunoglobulins (IVIG) are an attractive therapeutic tool for therapy of toxic epidermal necrolysis and severe forms of certain autoimmune diseases, including dermatomyositis, autoimmune blistering diseases, systemic vasculitis and lupus erythematodes. OBJECTIVES: Prompted by a case of IVIG-associated haemolytic anaemia, the effects of IVIG administrations on haematological parameters in patients with dermatological conditions were investigated. METHODS: Erythrocyte and leucocyte parameters were retrospectively analysed in 16 patients who had received IVIG at doses from 1 to 3 g/kg bodyweight (n = 35 cycles). The influence of IVIG on leucocyte survival was determined in vitro. RESULTS: Decreased absolute erythrocyte numbers, haemoglobin and haematocrit levels and a case of haemolytic anaemia were linked to transfusion of high-, but not low-dose IVIG. In contrast, leucopenia post-IVIG occurred in the vast majority of the recipients, unrelated to the administered IVIG amounts. In vitro investigations revealed a dose-dependent impairment of cell survival by IVIG in the neutrophil and monocyte, but not in the lymphocyte subpopulations. In several IVIG preparations, substantial amounts of blood group anti-A/anti-B antibodies were detected which could have accounted for the observed changes in the haematological parameters in our study cohort. CONCLUSIONS: IVIG products should be administered strictly according to indications. Commercially available IVIG products can contain blood group-specific antibodies that may induce haemolysis in some recipients. Monitoring of blood counts during applied IVIG therapy, especially when high doses are administered, is recommended.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Cicha A, Fischer MB, Wesinger A, et al. Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters. J Eur Acad Dermatol Venereol. 2017. PMID: 29114967. doi:10.1111/jdv.14671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。